How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Model Organism Market
- By Organism Type: Mouse, Zebrafish, Fruit Fly (Drosophila), Rat, Caenorhabditis elegans, Yeast
- By Application: Drug Discovery and Development, Genetic Research, Toxicology Studies, Disease Modeling, Agricultural Research
- By End User: Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Contract Research Organizations (CROs), Government and Regulatory Bodies
- By Model Organism Format: In Vivo Models, In Vitro Models, Transgenic Models, Knockout Models, Humanized Models
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Mouse leads By Organism Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 284 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.169 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.177 →
Full report · locked preview
Everything inside the Model Organism Market report
A complete, evidence-based study - 11 chapters and 119 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Organism Type 6
Application 5
End User 4
Model Organism Format 5
Companies profiled
Charles River Laboratories International Inc.
Envigo RMS LLC (a part of Inotiv)
Taconic Biosciences Inc.
Jackson Laboratory
Crown Bioscience Inc.
Oriental BioService Co. Ltd.
Biocytogen Pharmaceuticals Co. Ltd.
GemPharmatech Co. Ltd.
Cyagen Biosciences Inc.
Harlan Laboratories (now part of Envigo)
Janvier Labs
Transgenic Inc.
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Charles River Laboratories International Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Envigo RMS LLC (a part of Inotiv)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Taconic Biosciences Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Jackson Laboratory
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Crown Bioscience Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Oriental BioService Co. Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Biocytogen Pharmaceuticals Co. Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →GemPharmatech Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Cyagen Biosciences Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Harlan Laboratories (now part of Envigo)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Janvier Labs
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Transgenic Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →SAGE Labs (a division of BioIVT)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →InVivos Pte Ltd
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Shanghai Model Organisms Center
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$6,541M by 2033 · 8.7% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Mouse48.8
- Zebrafish17.3
- Fruit Fly (Drosophila)6.3
- Rat10.6
- Caenorhabditis elegans11.2
- Yeast5.8
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,108M → $2,197M · 8.9%
Europe$772.6M → $1,505M · 8.7%
Asia Pacific$705.4M → $1,389M · 8.8%
Latin America$436.7M → $763.4M · 7.2%
Middle East and Africa$335.9M → $681.0M · 9.2%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →8.652026
8.662027
8.662028
8.672029
8.692030
8.712031
8.712032
8.722033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Charles River Laboratories International Inc.25.9
- Envigo RMS LLC (a part of Inotiv)9.7
- Taconic Biosciences Inc.11.6
- Jackson Laboratory11.6
- Crown Bioscience Inc.4.3
- Oriental BioService Co. Ltd.8.8
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Organism Type38.1%
Application13.7%
End User20.0%
Model Organism Format28.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.6
- Europe23.0
- Asia Pacific21.3
- Latin America11.7
- Middle East and Africa10.4
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Charles River Laboratories International Inc. | 92 | 94 | 76 | 80 | 83 | 83 | 85 |
| Envigo RMS LLC (a part of Inotiv) | 93 | 81 | 69 | 79 | 73 | 70 | 78 |
| Taconic Biosciences Inc. | 86 | 85 | 86 | 67 | 67 | 86 | 80 |
| Jackson Laboratory | 67 | 60 | 77 | 57 | 57 | 76 | 66 |
| Crown Bioscience Inc. | 66 | 67 | 51 | 64 | 70 | 77 | 66 |
| Oriental BioService Co. Ltd. | 46 | 48 | 61 | 68 | 66 | 68 | 60 |
| Biocytogen Pharmaceuticals Co. Ltd. | 53 | 64 | 44 | 53 | 61 | 54 | 55 |
| GemPharmatech Co. Ltd. | 54 | 50 | 52 | 40 | 47 | 39 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Charles River Laboratories International Inc.
- Envigo RMS LLC (a part of Inotiv)
- Taconic Biosciences Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Charles River Laboratories International Inc. | ✓ | ✓ | ✓ | ◐ | ◐ | ◐ |
| Envigo RMS LLC (a part of Inotiv) | ✓ | ◐ | − | ◐ | ◐ | ✓ |
| Taconic Biosciences Inc. | ✓ | ✓ | ✓ | ◐ | ✓ | ◐ |
| Jackson Laboratory | − | − | ✓ | ◐ | − | ◐ |
| Crown Bioscience Inc. | ◐ | ✓ | ◐ | ◐ | ◐ | ◐ |
| Oriental BioService Co. Ltd. | ◐ | − | ◐ | − | ◐ | ◐ |
| Biocytogen Pharmaceuticals Co. Ltd. | − | ◐ | ◐ | − | − | − |
| GemPharmatech Co. Ltd. | ◐ | − | ◐ | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Charles River Laboratories International Inc.85
2Taconic Biosciences Inc.80
3Envigo RMS LLC (a part of Inotiv)78
4Jackson Laboratory66
5Crown Bioscience Inc.66
6Oriental BioService Co. Ltd.60
7Biocytogen Pharmaceuticals Co. Ltd.55
8GemPharmatech Co. Ltd.47
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Charles River Laboratories International Inc.Envigo RMS LLC (a part of Inotiv)Taconic Biosciences Inc.
Contender3
Focused players with pockets of strength.
Jackson LaboratoryCrown Bioscience Inc.Oriental BioService Co. Ltd.
Niche2
Specialists in a single segment or region.
Biocytogen Pharmaceuticals Co. Ltd.GemPharmatech Co. Ltd.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Organism Type in North America, then scale across Model Organism Market — a $325M beachhead inside a $6.19B market.
Beachhead (SOM)$325Mobtainable near-term
Serviceable (SAM)$2.15Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Mouse
Best fit — highest urgency & budget in Organism Type.
Economic buyer76 fit
Zebrafish
Strong fit — clear ROI and a fast path to value.
End user65 fit
Fruit Fly (Drosophila)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Organism Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel29%
Digital / self-serve17%
Marketplaces10%
Positioning & messaging
§GTM 2 · p.194 →For Organism Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Model Organism Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified22%
Evaluation15%
Closed-won8%
$11.3KCAC
$42KLTV
3.8:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Model Organism Market is a durable-growth opportunity — $2.25B by 2033, compounding at 6.1%.
TAM · 2025$1.41Btoday
TAM · 2033$2.25Bforecast
CAGR6.1%2027–2033
Cumulative$16.2Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$2.25BTotal addressable market
SAM$837MServiceable available market
SOM$142MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →6.1% CAGR
Demand compounds through 2033, outpacing GDP across Organism Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Organism Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$2.25BLarge & growingTAM by 2033 at 6.1% CAGR
$837MServiceable nowreachable with today’s model
$142MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.76BBear3.9% CAGR
$2.25BBase6.1% CAGR
$2.88BBull8.0% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Model Organism Market — a $2.52B market by 2033. Plan: grow share from 7.6% to 11.8%.
Market size · 2033$2.52Btotal addressable
Market CAGR4.3%2027–2033
Target share11.8%from 7.6% today
Revenue ambition$297Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.6% | 11.8% | Ahead |
| Revenue | $198M | $297M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Ahead |
| Gross margin | 30.2% | 41.7% | On track |
| Customer retention | 89.9% | 94.3% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Organism Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Organism Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $41M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Organism Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossAhead
- Input-cost & supply riskOn track
- Regulatory / policy changeAt risk
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Model Organism Market conversation — a $1.94B market you can size, segment and defend in minutes.
Market size · 2033$1.94Btotal opportunity
Growth6.7%CAGR to 2033
Addressable buyers1,521+accounts in scope
Typical ROI7.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Organism Type
Goal Grow share in Organism Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.4×return on cost, year one
< 2 mopayback period
$43K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Charles River Laboratories International Inc.Envigo RMS LLC (a part of Inotiv)Taconic Biosciences Inc.Jackson LaboratoryCrown Bioscience Inc.Oriental BioService Co. Ltd.Biocytogen Pharmaceuticals Co. Ltd.GemPharmatech Co. Ltd.+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Model Organism Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Model Organism Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Model Microbes Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportModel Animal Technology Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportModafinil Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportModafinil API Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportMoclobemide Tablet Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportMoclobemide Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportMoclobemide Film-coated Tablets Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportMobility Wheelchairs Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportMobility Assist Equipment Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportMobility Assist and Support Equipment Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportMobility Aids Products Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportMobility Aid Medical Device Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.